Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Luveltamab tazevibulin by Sutro Biopharma for Endometrial Cancer: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Endometrial Cancer. According to GlobalData,...
Luveltamab tazevibulin by Sutro Biopharma for Epithelial Ovarian Cancer: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Epithelial Ovarian Cancer. According to...
Luveltamab tazevibulin by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Refractory Acute Myeloid Leukemia. According...
Luveltamab tazevibulin by Sutro Biopharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Relapsed Acute Myeloid Leukemia. According...
Luveltamab tazevibulin by Sutro Biopharma for Peritoneal Tumor: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase II for Peritoneal Tumor. According to GlobalData,...
Luveltamab tazevibulin by Sutro Biopharma for Peritoneal Cancer: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Peritoneal Cancer. According to GlobalData,...
Luveltamab tazevibulin by Sutro Biopharma for Fallopian Tube Cancer: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase I for Fallopian Tube Cancer. According to...
Luveltamab tazevibulin by Sutro Biopharma for Epithelial Ovarian Cancer: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Epithelial Ovarian Cancer. According to...
Luveltamab tazevibulin by Sutro Biopharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Refractory Acute Myeloid Leukemia. According...
Luveltamab tazevibulin by Sutro Biopharma for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Luveltamab tazevibulin is under clinical development by Sutro Biopharma and currently in Phase III for Relapsed Acute Myeloid Leukemia. According...
MK-1484 by Sutro Biopharma for Solid Tumor: Likelihood of Approval
MK-1484 is under clinical development by Sutro Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase...